NASDAQ · COLL
Healthcare · Drug Manufacturers - Specialty & Generic
$23.73
Down-$0.09 (-0.37%)
Updated Nov 4, 2026, 8:10 PM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · COLL
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
COLL closed at $23.73 after 21 trading sessions, up 8.46% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $23.67 | $23.92 | $23.4901 | $23.73 | 525.6K |
| Nov 2, 2026 | $23.96 | $24.08 | $23.25 | $23.68 | 600.67K |
| Oct 30, 2026 | $24.28 | $24.50 | $23.66 | $23.80 | 401.93K |
| Oct 29, 2026 | $23.70 | $24.18 | $23.57 | $24.03 | 656.46K |
| Oct 28, 2026 | $22.78 | $23.31 | $22.665 | $23.23 | 406.09K |
| Oct 27, 2026 | $23.08 | $23.29 | $22.74 | $23.00 | 486.61K |
| Oct 26, 2026 | $22.96 | $23.52 | $22.92 | $23.21 | 518.25K |
| Oct 23, 2026 | $23.30 | $23.4899 | $22.151 | $22.96 | 662.37K |
| Oct 22, 2026 | $23.03 | $23.845 | $22.94 | $23.50 | 738.77K |
| Oct 21, 2026 | $23.13 | $23.15 | $22.575 | $22.915 | 480.42K |
| Oct 20, 2026 | $23.54 | $23.8443 | $22.895 | $23.23 | 536.15K |
| Oct 19, 2026 | $22.99 | $23.535 | $22.74 | $23.01 | 713.87K |
| Oct 16, 2026 | $23.40 | $23.41 | $22.855 | $23.19 | 558.74K |
| Oct 15, 2026 | $23.06 | $24.0422 | $23.06 | $23.18 | 1M |
| Oct 14, 2026 | $21.65 | $22.56 | $21.47 | $22.51 | 920.24K |
| Oct 13, 2026 | $22.05 | $22.21 | $21.46 | $21.53 | 846.42K |
| Oct 12, 2026 | $22.14 | $22.28 | $21.785 | $22.05 | 528.7K |
| Oct 9, 2026 | $22.01 | $22.40 | $21.77 | $22.09 | 438.44K |
| Oct 8, 2026 | $22.03 | $22.18 | $21.785 | $22.11 | 532.92K |
| Oct 7, 2026 | $21.88 | $22.15 | $21.73 | $21.93 | 783.47K |
| Oct 6, 2026 | $22.06 | $22.32 | $21.675 | $21.88 | 634.06K |
The latest Smart Investors Daily articles mentioning COLL.
Company
Market Activity
Research & News
COLL research
Company profile and research snapshot.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 23, 2026 | Oppenheimer | Outperform | — |
| Sep 9, 2026 | Leerink Partners | Outperform | — |
| Sep 9, 2026 | Truist Securities | Buy | — |
| Aug 19, 2026 | Barclays | Overweight | — |
| Aug 7, 2026 | Piper Sandler | Neutral | — |
No generated briefing is available yet.
Yahoo · Oct 30, 2026
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
Yahoo · Oct 29, 2026
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Yahoo · Oct 29, 2026
New multi-year partnership combines youth coach training, an annual Sports for All Summit, and sensory inclusion programs to support neurodivergent children and families Collegium and Boston Legacy FC in action A partnership on the pitch. Adaptive soccer clinic in action Working to make soccer more accessible through an adaptive soccer clinic. Adaptive Soccer Clinic Children at the adaptive soccer clinic from Oct. 24, 2026. Adaptive Soccer Clinic Participation Providing tools to coach children w
Yahoo · Oct 27, 2026
HCA's Q3 earnings and revenues beat estimates on higher admissions and ER visits, while rising costs and fewer surgeries temper growth.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning COLL.
